Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
Myriad Genetics (NASDAQ: MYGN) is set to release its Q2 earnings on August 4, 2022, prior to market opening, followed by a conference call at 4:30 PM EDT. Key executives, including CEO Paul J. Diaz, will discuss the company's financial performance and updates for the period ending June 30, 2022. Additionally, an Investor Day is scheduled for August 11, 2022, focusing on strategic growth opportunities and the R&D pipeline.
Myriad is recognized for its contributions to genetic testing and precision medicine, and was named among Fast Company’s World’s Most Innovative Companies for 2022.
- None.
- None.
SALT LAKE CITY, July 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Aug. 4, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be released the same day prior to the market opening.
During the call, Paul J. Diaz, president and chief executive officer, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provide a financial overview and business update of Myriad’s performance for the period ending June 30, 2022.
The dial-in number for domestic callers is 1-800-918-9482. International callers may dial 1-212-231-2929. All callers will be asked to reference reservation number 22019815. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call along with a slide presentation will be available through a live webcast at www.myriad.com.
Myriad will also host an Investor Day on Aug. 11, 2022, to provide a strategic business update and overview of the company’s growth opportunities, research and development pipeline, and technology initiatives. More information can be found here.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
| Media Contact: Megan Manzari (385) 318-3718 Megan.Manzari@myriad.com | Investor Contact: Foster Harris (385) 350-8015 Foster.Harris@myriad.com |
FAQ
When will Myriad Genetics release its second-quarter earnings?
What time is the Myriad Genetics earnings conference call?
Who will speak at the Myriad Genetics Q2 earnings call?
What is the purpose of Myriad Genetics' Investor Day?
